BlackSky Wins $25M International Defense Contract, Reinforcing Growth Narrative but Cash Conversion Risks Persist

What happened

BlackSky announced a $25 million, multi-year contract with a major international defense customer, aligning with its strategy to scale international demand. The DeepValue report highlights that BlackSky's investment thesis centers on converting its $345M backlog into sustained revenue while managing working-capital volatility. This win supports the narrative of international expansion, but the report cautions that contract announcements alone don't ensure cash conversion or profitability, given past issues with unbilled assets and AR. With FY2025 adjusted EBITDA at only $0.9M and high capex needs, this contract must translate into timely billings to improve liquidity and avoid further financing. Overall, while positive, the news doesn't address near-term risks like U.S. budget clarity or backlog conversion discipline, keeping the 'WAIT' rating intact.

Implication

The contract adds to BlackSky's backlog, which is already at $345M, but investors should monitor if it converts into revenue without re-inflating unbilled contract assets from the Q4'25 level of ~$28.6M. It aligns with management's push to reduce reliance on volatile U.S. demand, yet the report emphasizes ongoing uncertainty in EOCL funding and the need for Q2'26 visibility. Cash flow improvement is critical, as Q4'25 free cash flow was -$13.6M, and this contract must contribute to operating cash flow without delaying collections. Margin pressure remains a concern, with FY2025 cost of sales rising to 33% of revenue, limiting EBITDA growth despite revenue increases. Investors should await Q2'26 results for evidence of EOCL tasking recovery and sustained quarterly revenue above $32M before considering a rating upgrade.

Thesis delta

This contract win slightly strengthens the bull case for international scaling, as it demonstrates demand diversification. However, it doesn't materially shift the investment thesis, as core issues—cash conversion, U.S. budget visibility, and profitability—remain unchanged, and the 'WAIT' rating is still appropriate until operational evidence emerges.